Steven Thomas Fletcher

US Patent:

20210317097, Oct 14, 2021

Filed:

Jun 16, 2021

Appl. No.:

17/349468

Inventors:

- Baltimore MD, US
Jeffrey D. HASDAY - Timonium MD, US
Steven FLETCHER - Baltimore MD, US

International Classification:

C07D 295/03

Abstract:

Compounds that inhibit p38α MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.

US Patent:

20200331874, Oct 22, 2020

Filed:

May 11, 2020

Appl. No.:

16/872114

Inventors:

- Baltimore MD, US
Jeffrey D. HASDAY - Timonium MD, US
Steven FLETCHER - Baltimore MD, US

International Classification:

C07D 295/03

Abstract:

Compounds that inhibit p38α MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.

US Patent:

20200283417, Sep 10, 2020

Filed:

Oct 5, 2017

Appl. No.:

16/344733

Inventors:

- Baltimore MD, US
Rena G. Lapidus - Baltimore MD, US
Brandon A. Carter-Cooper - Manchester MD, US
Steven Fletcher - Baltimore MD, US
Dana Ferraris - Eldersburg MD, US
Edward A. Sausville - Edgewater MD, US

International Classification:

C07D 403/10
C07D 203/14
C07C 225/30
A61P 35/02

Abstract:

The invention relates to new amino dimeric naphthoquinone compounds with antileukemic activity. Compounds of the invention demonstrated increased aqueous solubility compared to previously available dimeric naphthoquinones and potent nanomolar inhibition of cell survival in AML cells. Preferred compounds contained an aziridine or a secondary amino alcohol pharmacophore.

US Patent:

20200216394, Jul 9, 2020

Filed:

Dec 23, 2019

Appl. No.:

16/724821

Inventors:

- Baltimore MD, US
Alexander MacKerell - Baltimore MD, US
Steven Fletcher - Baltimore MD, US
Jamal Chauhan - Baltimore MD, US

International Classification:

C07D 213/26
A61P 31/04

Abstract:

Newly synthesized derivatives of BAS00127538 have been discovered to possess antibiotic activity and to combat resistant bacterial strains. Compounds and pharmaceutical compositions containing these compounds are described, and are based on a generic scaffold structure. Synthetic methods and methods of using the compounds also are described. Preferred compounds bind to Lipid II with high affinity, have markedly reduced cytotoxicity compared to BAS00127538, and retain activity against drug-resistant strains of Enterococci. They are stable in plasma, have dramatically improved pharmacokinetic and pharmacodynamics properties, and possess in vivo efficacy in a mouse model of sepsis.

US Patent:

20190358232, Nov 28, 2019

Filed:

Jan 11, 2018

Appl. No.:

16/476845

Inventors:

- Pittsburgh PA, US
- Baltimore MD, US
Yohei Doi - Pittsburgh PA, US
Eric J. Sundberg - Baltimore MD, US
Erik H. Klontz - Baltimore MD, US
Steven Fletcher - Baltimore MD, US

Assignee:

University of Pittsburgh - Of the Commonwealth System of Higher Education - Pittsburgh PA
University of Maryland, Baltimore - Baltimore MD

International Classification:

A61K 31/519
A61K 31/665
C07D 519/00
A61P 31/04
C07D 487/04

Abstract:

Compounds, pharmaceutical compositions, and methods for reversing fosfomycin resistance are disclosed. Embodiments of the disclosed compounds inhibit fosfomycin-inhibiting enzymes. Some embodiments of the compounds are FosA inhibitors. The disclosed pharmaceutical compositions include (i) fosfomycin or a pharmaceutically acceptable salt thereof and (ii) a compound, or a pharmaceutically acceptable salt thereof, which inhibits a fosfomycin-inhibiting enzyme. A method of inhibiting growth of a fosfomycin-resistant bacterium includes contacting the bacterium with (i) fosfomycin or a pharmaceutically acceptable salt thereof and (ii) an effective amount of a disclosed compound or a pharmaceutically acceptable salt thereof.

US Patent:

20190002426, Jan 3, 2019

Filed:

Dec 20, 2016

Appl. No.:

16/064276

Inventors:

- Baltimore MD, US
Alexander MacKerell - Baltimore MD, US
Steven Fletcher - Baltimore MD, US
Jamal Chauhan - Baltimore MD, US

International Classification:

C07D 309/34
C07D 403/06
C07D 471/06
A61P 31/04

Abstract:

Newly synthesized derivatives of BAS00127538 have been discovered to possess antibiotic activity and to combat resistant bacterial strains. Compounds and pharmaceutical compositions containing these compounds are described, and are based on a generic scaffold structure. Synthetic methods and methods of using the compounds also are described. Preferred compound 6jc48-1 ((E)-2,4-bis(4-bromophenyl)-6-(4-(dimethyl-amino)styryl)pyrylium boron tetrafluoride salt) binds to Lipid II with high affinity, has markedly reduced cytotoxicity than BAS00127538, and retains activity against drug-resistant strains of . It is stable in plasma, has dramatically improved pharmacokinetic and pharmacodynamics properties, and possesses in vivo efficacy in a mouse model of sepsis.

US Patent:

20140296307, Oct 2, 2014

Filed:

Mar 27, 2014

Appl. No.:

14/227243

Inventors:

- Baltimore MD, US
STEVEN FLETCHER - BALTIMORE MD, US

Assignee:

University of Maryland, Baltimore - Baltimore MD

International Classification:

C07D 271/12

US Classification:

514364, 548126

Abstract:

The present invention relates compounds and compositions for interfering with the association of Myc and Max. These compounds and compositions are useful in methods for inhibiting growth or proliferation of a cell. Methods of inhibiting growth or proliferation of a cell comprise contacting the cell with an amount of a compound that interferes with Myc and Max association effective to inhibit growth or proliferation of the cell. The compounds exhibit increased inhibitory activity against c-Myc relative to the known c-Myc inhibitor small-molecule benzofurazan N-([1,1′-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine (10074-G5).

US Patent:

20140256817, Sep 11, 2014

Filed:

Mar 7, 2014

Appl. No.:

14/200774

Inventors:

- Baltimore MD, US
Steven FLETCHER - Baltimore MD, US

Assignee:

UNIVERSITY OF MARYLAND, BALTIMORE - Baltimore MD

International Classification:

C07C 237/34
C07C 237/30

US Classification:

514563, 564158, 514616, 562441

Abstract:

Small-molecule scaffolds based on 1,2-diphenylacetylene that accurately replicate the spatial and angular projections of several side chains on both faces of an α-helix, specifically the i and i+7 side chains on one face, and the i and i+2 side chains on the other. The amphipathic α-helix mimetic can be used to disrupt disease-promoting protein-protein interactions that are mediated by α-helices.